GKOSGlaukos Corporation
Price
+98%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth steady, the market undecided.
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Glaukos Corporation (GKOS) reported revenue of $186M in Q2 2026 (quarter ended Jun 30, 2026), up 50% from the same quarter a year earlier. That came with a gross margin of 82% and net loss of $18M. For the full year FY2025, revenue was $507M (+32% year on year) and net income −$188M. Its largest product in Q2 2026 was Glaucoma at $119M, 81% of the disclosed total, well ahead of Corneal Health at 19%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases. Logo.Regulation FD disclosure · press release
- Jul 29, 2026Vice President, Investor Relations & Corporate Affairs.Earnings release · press release
- May 4, 2026Disclaimer All statements other than.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $146.7MThe company’s own SEC segment disclosure.
- Glaucoma$118.5M81%
- Corneal Health$28.2M19%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.